Neurogene Inc.
corporate_fare Company Profile
Neurogene Inc. (NASDAQ:NGNE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for NGNE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for NGNE spans 10-Q, 8-K, 424B5, 10-K.
Recent high-impact activity:
- Neurogene Q3 10-Q: $94.4M Nine-Month Loss, $359.7M Cash Into Q1 2029
- Neurogene Posts $29.0M Q3 Loss, $359.7M Cash Through Q1 2029, Embolden Data 2H 2027
- Neurogene Q2 Loss Widens but Cash Runway Extended to 2029; PPQ Campaign Initiated
- Neurogene Reports Q2 2026 Results, Extends Cash Runway into 2029, and Initiates PPQ Campaign for NGN-401
- Neurogene Initiates PPQ Campaign, Extends Cash Runway to 2029 After Q2 Results
Financial Snapshot
Short Interest & Short Volume
16.95 days to coverFINRA reported short interest of 5,685,998 shares in NGNE as of the October 30, 2026 settlement, a 11.6% increase from the prior period — about 16.9 days to cover at its recent average daily volume. On November 20, 2026, 70.2% of NGNE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for NGNE, detected from its recent SEC filings · based on capital-structure filings through 2026-07-01.
Public Offering Priced · Significant Capital Raise
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →